The use of pharmacoeconomic data in managed care: closing the credibility gap.
According to the author, MCOs rarely incorporate the findings of pharmacoeconomic studies in formulary decision making. As a result, managed care plans fail to examine the costs and cost savings of a new drug across the whole health care continuum, but see only how it directly affects their system. Credible pharmacoeconomic data can be valuable to formulary decision makers, offering them a broader perspective. However, what constitutes credible pharmacoeconomic data?